Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
This study is currently recruiting participants.
Verified June 2013 by Bayer
Sponsor:
Bayer
Collaborator:
Onyx Therapeutics, Inc.
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT01234337
First received: October 4, 2010
Last updated: June 18, 2013
Last verified: June 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | November 2013 (Final data collection date for primary outcome measure) |